Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 18;14(8):e28130.
doi: 10.7759/cureus.28130. eCollection 2022 Aug.

Management of Atopic Dermatitis: The Role of Tacrolimus

Badar Uddin Umar  1 , Sayeeda Rahman  2 , Siddhartha Dutta  3 , Tariqul Islam  4 , Nadia Nusrat  5 , Kona Chowdhury  6 , Wan Farizatul Shima Binti Wan Ahmad Fakuradzi  7 , Mainul Haque  8
Affiliations
Review

Management of Atopic Dermatitis: The Role of Tacrolimus

Badar Uddin Umar et al. Cureus. .

Abstract

Atopic dermatitis (AD) is a long-lasting inflammatory dermatological condition characterized by itchy, eczematous, sparsely tiny blisters that hold a clear watery substance. Additionally, the diseased skin can suppurate, occasionally with weeping with thickening of the affected skin. This is considered one of the top skin disorders involving both children and adult populations globally. The principal therapeutic intervention for AD is long-standing topical glucocorticoids, which have been used for several decades. Corticosteroid therapy brings several adverse drug effects (ADRs), including irreversible skin atrophy. Tacrolimus belongs to the class of calcineurin inhibitors, which is a type of immunomodulator possessing promising efficacy in treating AD. Topical tacrolimus is an effective and safe non-corticosteroid substitute treatment for AD. We reviewed the available literature to compare and institute the safety, efficacy, and effectiveness of tacrolimus when equated to corticosteroid therapy in managing AD.

Keywords: atopic dermatitis; capacity; corticosteroid medication; function; pharmacological interventions; tacrolimus.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tacrolimus in dermatology. Dé Tran QH, Guay E, Chartier S, Tousignant J. J Cutan Med Surg. 2001;5:329–335. - PubMed
    1. FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects. Wallemacq PE, Reding R. Clin Chem. 1993;39:2219–2228. - PMC - PubMed
    1. Tacrolimus toxicity with minimal clinical manifestations: a case report and literature review. Haroon N, Singh A, Bhat ZY. Am J Ther. 2016;23:0–4. - PubMed
    1. Tacrolimus in dermatology-pharmacokinetics, mechanism of action, drug interactions, dosages, and side effects: part I. Sehgal VN, Srivastava G, Dogra S. Skinmed. 2008;7:27–30. - PubMed
    1. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. J Am Acad Dermatol. 2001;44:0–38. - PubMed

LinkOut - more resources